Abstract
This review evaluates the current literature based on the impact of antibiotics on the intestinal microbiota and the critical role of intestinal bacteria in controlling infection and subsequent clinical disease caused by STEC and Salmonella, and the transmissibility of these important pathogens.A number of studies have indicated that antibiotic therapy could result in unexpected changes in the clinical picture of disease. This is observed, for example, in the case of infections associated with Shiga-toxin-producing Escherichia coli (STEC), when antibiotics used in treatment of the disease may increase the risk of hemolytic uremic syndrome (HUS) and thus fatal outcomes. In the case of such infections, treatment with antibiotics is usually discouraged. The use of antibiotics could cause also undesirable changes in the intestinal microbial flora and prolonged pathogen shedding, which is observed in the case of Salmonella infections. Inappropriate antibiotic therapy can result in Salmonella remaining in the host’s cells (intracellular) and thus resulting in further asymptomatic carriage and a further complication is the development of resistance.
Keywords: Escherichia coli, EHEC, STEC, HUS, Salmonella, antibiotics, side effect, microbiota, asymptomatic carriage.
Current Pharmaceutical Design
Title:Impact of Antibiotics on the Intestinal Microbiota and on the Treatment of Shiga-toxin-Producing Escherichia coli and Salmonella Infections
Volume: 20 Issue: 28
Author(s): Jolanta Szych, Tomasz Wolkowicz, Roberto La Ragione and Grzegorz Madajczak
Affiliation:
Keywords: Escherichia coli, EHEC, STEC, HUS, Salmonella, antibiotics, side effect, microbiota, asymptomatic carriage.
Abstract: This review evaluates the current literature based on the impact of antibiotics on the intestinal microbiota and the critical role of intestinal bacteria in controlling infection and subsequent clinical disease caused by STEC and Salmonella, and the transmissibility of these important pathogens.A number of studies have indicated that antibiotic therapy could result in unexpected changes in the clinical picture of disease. This is observed, for example, in the case of infections associated with Shiga-toxin-producing Escherichia coli (STEC), when antibiotics used in treatment of the disease may increase the risk of hemolytic uremic syndrome (HUS) and thus fatal outcomes. In the case of such infections, treatment with antibiotics is usually discouraged. The use of antibiotics could cause also undesirable changes in the intestinal microbial flora and prolonged pathogen shedding, which is observed in the case of Salmonella infections. Inappropriate antibiotic therapy can result in Salmonella remaining in the host’s cells (intracellular) and thus resulting in further asymptomatic carriage and a further complication is the development of resistance.
Export Options
About this article
Cite this article as:
Szych Jolanta, Wolkowicz Tomasz, Ragione La Roberto and Madajczak Grzegorz, Impact of Antibiotics on the Intestinal Microbiota and on the Treatment of Shiga-toxin-Producing Escherichia coli and Salmonella Infections, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/13816128113196660730
DOI https://dx.doi.org/10.2174/13816128113196660730 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Severe Meningococcal Infections in Children and Adolescents
Current Pediatric Reviews CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Cephalosporins Associated Pseudomembraneous Colitis in an Elderly Male Patient - A Case Report
Current Drug Safety A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Dural Venous Sinuses: What We Need to Know
Current Medical Imaging Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Conformational Flexibility in Designing Peptides for Immunology: The Molecular Dynamics Approach
Current Computer-Aided Drug Design Chemoinfectomics in Drug Design and Development
Anti-Infective Agents Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry Combat Pneumococcal Infections: Adhesins as Candidates for Protein- Based Vaccine Development
Current Drug Targets Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Synergistic Effect of Combined HIV/HCV Immunogens: A Combined HIV-1/HCV Candidate Vaccine Induces a Higher Level of CD8+ T Cell-Immune Responses in HLA-A2.1 Mice
Current HIV Research